![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 1nfection (Part A of C-CREST-1 & 2)
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17, San Francisco
![AASLD1.gif](../images/112015/112015-2/AASLD1.gif)
![AASLD2.gif](../images/112015/112015-2/AASLD2.gif)
![AASLD3.gif](../images/112015/112015-2/AASLD3.gif)
![AASLD4.gif](../images/112015/112015-2/AASLD4.gif)
![AASLD5.gif](../images/112015/112015-2/AASLD5.gif)
![AASLD6.gif](../images/112015/112015-2/AASLD6.gif)
![AASLD7.gif](../images/112015/112015-2/AASLD7.gif)
![AASLD8.gif](../images/112015/112015-2/AASLD8.gif)
![AASLD9.gif](../images/112015/112015-2/AASLD9.gif)
![AASLD10.gif](../images/112015/112015-2/AASLD10.gif)
![AASLD11.gif](../images/112015/112015-2/AASLD11.gif)
![AASLD12.gif](../images/112015/112015-2/AASLD12.gif)
![AASLD13.gif](../images/112015/112015-2/AASLD13.gif)
![AASLD14.gif](../images/112015/112015-2/AASLD14.gif)
![AASLD15.gif](../images/112015/112015-2/AASLD15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|